1176326-75-2

Upstream product

• 10031-93-3 ethyl 4-phenylbutyrate 
• 1176327-20-0 4-[4-bromo-3-(2-methoxyethoxy)benzyl]piperidine hydrochloride 
• 1176328-85-0 2-(8-oxo-5,6,7,8-tetrahydronaphthalen-2-yl)ethyl 4-methylbenzenesulfonate 
• 71665-59-3 4-(4-acetylphenyl)butyric acid ethyl ester 
• 100117-94-0 4-<4-(carboxymethyl)phenyl>butyric acid 
• 1176328-86-1 7-(2-hydroxyethyl)-1,2,3,4-tetrahydronaphthalen-1-ol 
• 1176328-84-9 7-(2-hydroxyethyl)-3,4-dihydronaphthalen-1(2H)-one 

Relevant academic research and scientific papers

Discovery of DSP-1053, a novel benzylpiperidine derivative with potent serotonin transporter inhibitory activity and partial 5-HT1A receptor agonistic activity

We have previously shown that SMP-304, a serotonin uptake inhibitor with weak 5-HT1A partial agonistic activity, may act under high serotonin levels as a 5-HT1A antagonist that improves the onset of paroxetine in the rat swimming test. However, SMP-304 is mostly metabolized by CYP2D6, indicating limited efficacy among individuals and increased side effects. To reduce CYP2D6 metabolic contribution and enhance SERT/5-HT1A binding affinity, we carried out a series of substitutions at the bromine atom in the left part of the benzene ring of SMP-304 and replaced the right part of SMP-304 with a chroman-4-one. This optimization work led to the identification of the antidepressant candidate DSP-1053 as a potent SERT inhibitor with partial 5-HT1A receptor agonistic activity. DSP-1053 showed low CYP2D6 metabolic contribution and a robust increase in serotonin levels in the rat frontal cortex.

BENZYLPIPERIZINE COMPOUND

Disclosed is a benzylpiperizine compound represented by formula (1) or a pharmaceutically acceptable salt thereof, which is useful as a medicinal agent such as an antidepressant agent. (In the formula (1), R1 represents a hydrogen atom or a met